---
layout: default
title: Ascorbic Acid
parent: 僅模型預測 (L5)
nav_order: 67
evidence_level: L5
indication_count: 10
---

# Ascorbic Acid
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ASCORBIC ACID: From Vitamin C Deficiency to Non-Syndromic Esophageal Malformation

## One-Sentence Summary

Ascorbic acid (Vitamin C) is an essential water-soluble micronutrient, best known as the therapeutic agent for scurvy and vitamin C deficiency, with no formal approved indication on record in Canada.
The TxGNN model predicts it may be effective for **Non-Syndromic Esophageal Malformation**, with **0 clinical trials** and **0 publications** currently supporting this direction.
Despite an extremely high prediction score (99.96%), this result is assessed as a likely knowledge graph false positive with no supporting mechanistic or clinical evidence.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Vitamin C deficiency / Scurvy (established historical use; no Canada regulatory approval on record) |
| Predicted New Indication | Non-syndromic esophageal malformation |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| Canada Market Status | Not marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from this evidence pack. Based on well-established pharmacology, ascorbic acid is an essential cofactor for prolyl and lysyl hydroxylases — the enzymes responsible for post-translational modification of collagen precursors. Deficiency leads to defective collagen cross-linking, manifest as capillary fragility, impaired wound healing, and classic scurvy. It also functions as a potent water-soluble antioxidant, supports catecholamine biosynthesis, enhances non-heme iron absorption, and modulates immune cell function.

Non-syndromic esophageal malformation is a congenital structural anomaly of the esophagus arising from disrupted embryogenesis. While ascorbic acid is theoretically involved in connective tissue formation during development, there is no established pathway by which post-natal supplementation could correct an already-formed structural malformation of the esophagus.

The internal evidence pack commentary explicitly flags this prediction as a likely **false positive**: the high TxGNN score most plausibly reflects topological co-occurrence of esophageal tissue nodes within the knowledge graph, rather than a genuine biological signal. This type of artifact is a known limitation of graph-based drug repurposing models when applied to rare congenital structural diseases.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

No DIN (Drug Identification Number) records found for Ascorbic Acid in the Canada Health regulatory database.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There is a complete absence of clinical, preclinical, and mechanistic evidence supporting ascorbic acid in non-syndromic esophageal malformation; the prediction is flagged as a knowledge graph topology artifact, and no biologically plausible intervention pathway exists for a congenital structural defect using a water-soluble vitamin.

**To proceed, the following is needed:**
- Knowledge graph audit: verify whether the high score reflects genuine biological edges or topological noise (e.g., shared esophagus-related hub nodes)
- Mechanism of action data from DrugBank (DB00126) to formally assess any embryological relevance
- Developmental biology review: assess whether ascorbic acid influences esophageal morphogenesis in animal models
- Regulatory data: obtain Canada package insert warnings and contraindications to support basic safety profiling

> **Research Disclaimer:** This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

